Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 8.03
DXCM's Cash to Debt is ranked higher than
78% of the 291 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.74 vs. DXCM: 8.03 )
DXCM' s 10-Year Cash to Debt Range
Min: 0.6   Max: No Debt
Current: 8.03

Equity to Asset 0.69
DXCM's Equity to Asset is ranked higher than
77% of the 285 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.63 vs. DXCM: 0.69 )
DXCM' s 10-Year Equity to Asset Range
Min: -0.44   Max: 0.88
Current: 0.69

-0.44
0.88
F-Score: 6
Z-Score: 36.17
M-Score: -3.58
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) -18.06
DXCM's Operating margin (%) is ranked higher than
55% of the 287 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.44 vs. DXCM: -18.06 )
DXCM' s 10-Year Operating margin (%) Range
Min: -2272.81   Max: -18.06
Current: -18.06

-2272.81
-18.06
Net-margin (%) -18.63
DXCM's Net-margin (%) is ranked higher than
55% of the 287 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.65 vs. DXCM: -18.63 )
DXCM' s 10-Year Net-margin (%) Range
Min: -2147.42   Max: -18.63
Current: -18.63

-2147.42
-18.63
ROE (%) -35.43
DXCM's ROE (%) is ranked higher than
53% of the 283 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.68 vs. DXCM: -35.43 )
DXCM' s 10-Year ROE (%) Range
Min: -644.81   Max: -35.43
Current: -35.43

-644.81
-35.43
ROA (%) -24.33
DXCM's ROA (%) is ranked higher than
53% of the 290 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.24 vs. DXCM: -24.33 )
DXCM' s 10-Year ROA (%) Range
Min: -134.12   Max: -24.33
Current: -24.33

-134.12
-24.33
ROC (Joel Greenblatt) (%) -98.63
DXCM's ROC (Joel Greenblatt) (%) is ranked higher than
56% of the 288 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 22.38 vs. DXCM: -98.63 )
DXCM' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1666.94   Max: -98.63
Current: -98.63

-1666.94
-98.63
Revenue Growth (%) 38.30
DXCM's Revenue Growth (%) is ranked higher than
97% of the 248 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.70 vs. DXCM: 38.30 )
DXCM' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 103.1
Current: 38.3

0
103.1
EBITDA Growth (%) -25.50
DXCM's EBITDA Growth (%) is ranked higher than
53% of the 210 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 6.40 vs. DXCM: -25.50 )
DXCM' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: 0.6
Current: -25.5

0
0.6
EPS Growth (%) -24.30
DXCM's EPS Growth (%) is ranked higher than
56% of the 220 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.90 vs. DXCM: -24.30 )
DXCM' s 10-Year EPS Growth (%) Range
Min: -40.1   Max: 37.1
Current: -24.3

-40.1
37.1
» DXCM's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2013

DXCM Guru Trades in Q1 2013

George Soros 100,000 sh (New)
Jim Simons 171,843 sh (+57.88%)
Ron Baron 1,388,587 sh (+11.09%)
Manning & Napier Advisors, Inc 2,007,710 sh (+1.83%)
Mario Gabelli 76,000 sh (unchged)
Pioneer Investments Sold Out
Steven Cohen Sold Out
RS Investment Management 928,398 sh (-18.49%)
» More
Q2 2013

DXCM Guru Trades in Q2 2013

George Soros 100,000 sh (unchged)
Stanley Druckenmiller Sold Out
Ron Baron 1,387,037 sh (-0.11%)
Mario Gabelli 75,000 sh (-1.32%)
RS Investment Management 740,028 sh (-20.29%)
Jim Simons 117,143 sh (-31.83%)
Manning & Napier Advisors, Inc 1,197,900 sh (-40.34%)
» More
Q3 2013

DXCM Guru Trades in Q3 2013

Jim Simons 207,343 sh (+77%)
Mario Gabelli 75,000 sh (unchged)
Manning & Napier Advisors, Inc Sold Out
George Soros Sold Out
Ron Baron 1,369,154 sh (-1.29%)
RS Investment Management 621,381 sh (-16.03%)
» More
Q4 2013

DXCM Guru Trades in Q4 2013

Paul Tudor Jones 8,059 sh (New)
Jim Simons 557,543 sh (+168.9%)
Ron Baron 1,357,357 sh (-0.86%)
Mario Gabelli 74,000 sh (-1.33%)
RS Investment Management 477,381 sh (-23.17%)
» More
» Details

Insider Trades

Latest Guru Trades with DXCM

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
George Soros 2013-09-30 Sold Out 0.02%$21.78 - $29.19 $ 36.5844%0
George Soros 2013-03-31 New Buy0.02%$13.59 - $17.05 $ 36.58140%100000
Ron Baron 2012-12-31 New Buy0.11%$12.3 - $14.95 $ 36.58173%1250000
George Soros 2011-09-30 Sold Out 0.0025%$10.3 - $15.66 $ 36.58182%0
George Soros 2011-06-30 New Buy$13.05 - $16.72 $ 36.58140%12500
Mario Gabelli 2011-03-31 Reduce -55.46%0.01%$13.3 - $15.79 $ 36.58154%77500
George Soros 2011-03-31 Sold Out $13.3 - $15.79 $ 36.58154%0
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 31.60
DXCM's P/B is ranked lower than
79% of the 278 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.77 vs. DXCM: 31.60 )
DXCM' s 10-Year P/B Range
Min: 3.88   Max: 209.25
Current: 31.6

3.88
209.25
P/S 16.30
DXCM's P/S is ranked lower than
86% of the 292 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.60 vs. DXCM: 16.30 )
DXCM' s 10-Year P/S Range
Min: 6.36   Max: 1058.5
Current: 16.3

6.36
1058.5
EV-to-EBIT 33.30
DXCM's EV-to-EBIT is ranked lower than
65% of the 247 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 18.32 vs. DXCM: 33.30 )
DXCM' s 10-Year EV-to-EBIT Range
Min: 1   Max: 4.1
Current: 33.3

1
4.1

Valuation & Return

vs
industry
vs
history
Price/Net Cash 166.30
DXCM's Price/Net Cash is ranked lower than
88% of the 68 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 17.30 vs. DXCM: 166.30 )
DXCM' s 10-Year Price/Net Cash Range
Min: 5.94   Max: 160.95
Current: 166.3

5.94
160.95
Price/Net Current Asset Value 65.30
DXCM's Price/Net Current Asset Value is ranked lower than
82% of the 118 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 13.00 vs. DXCM: 65.30 )
DXCM' s 10-Year Price/Net Current Asset Value Range
Min: 5.83   Max: 63.23
Current: 65.3

5.83
63.23
Price/Tangible Book 34.20
DXCM's Price/Tangible Book is ranked lower than
92% of the 232 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.80 vs. DXCM: 34.20 )
DXCM' s 10-Year Price/Tangible Book Range
Min: 4.88   Max: 35.32
Current: 34.2

4.88
35.32
Price/Median PS Value 1.10
DXCM's Price/Median PS Value is ranked higher than
66% of the 268 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.10 vs. DXCM: 1.10 )
DXCM' s 10-Year Price/Median PS Value Range
Min: 0.55   Max: 8.43
Current: 1.1

0.55
8.43
Forward Rate of Return (Yacktman) -21.89
DXCM's Forward Rate of Return (Yacktman) is ranked higher than
55% of the 217 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.90 vs. DXCM: -21.89 )
DXCM' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 36.5   Max: 57
Current: -21.89

36.5
57

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies
Compare:WST, BAX, COV, TMO, COO » details
Traded in other countries:DC4.Germany
Dexcom Inc is a Delaware Corporation, incepted in May 1999. It is a medical device company focused on the design, development and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes and for use by healthcare providers in the hospital for the treatment of both diabetic and non-diabetic patients. The majority of its product revenue comes from sales of its SEVEN PLUS ambulatory continuous glucose monitoring system. The Company's SEVEN PLUS is more invasive than current self-monitored glucose testing systems, including single-point finger stick devices, and patients may be unwilling to insert a sensor in their body, especially if their current diabetes management involves no more than two finger sticks per day. Moreover, patients may not perceive the benefits of continuous glucose monitoring and may be unwilling to change their current treatment regimens. The SEVEN PLUS incorporates additional user interface and algorithm enhancements that are intended to make its glucose monitoring function more accurate and customizable. To address the in-hospital patient population, it entered into an exclusive agreement with Edwards to develop jointly and market a specific product platform for the in-hospital glucose monitoring market, with an initial focus on the development of an intravenous sensor specifically for the critical care market. The new SEVEN PLUS is an easy-to-use wireless device that is designed to simplify the patient's glucose management. The SEVEN PLUS measures the patient's glucose 24/7. It shows a new glucose reading every 5 minutes and updates the trend-wave to show the where glucose level is, where it has been, and where it's headed. The SEVEN PLUS also shows how fast the body's glucose levels are changing. The SEVEN PLUS is designed to help avoid highs and lows and to help keep the glucose between the lines of the target zones. Glucose data can be displayed on the monitor at one hour, 3 hours, 6 hours, 12 hours and 24 hours.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide